PolyMedix Progresses With Drug That Mimics Body’s Natural Protective Proteins
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novel antibiotic brilacidin meets endpoints in Phase IIa study of 215 patients with acute bacterial skin and skin structure infection. Design went further than requirements in FDA guidance for ABSSSI.